Buoyed by semaglu­tide suc­cess, No­vo Nordisk un­corks plans for $2.58B man­u­fac­tur­ing ex­pan­sion in Den­mark

No­vo Nordisk scored a pair of dou­ble wins the last cou­ple years with the ap­proval of two dif­fer­ent forms of semaglu­tide, the com­pa­ny’s newest block­buster prod­uct line. Now, No­vo is set­ting aside a se­ri­ous pile of cash to take its man­u­fac­tur­ing ops in­to the fu­ture as the com­pa­ny looks to lev­el up.

No­vo will in­vest rough­ly $2.58 bil­lion (DKK 17 bil­lion) to great­ly ex­pand its man­u­fac­tur­ing foot­print at its cen­tral hub in Kalund­borg, Den­mark, with three new fa­cil­i­ties and the ex­pan­sion of a fourth on the way, the com­pa­ny said this week.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN